[2]Ying Z,et al.Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2021 Feb;10(3):999-1011. https://w...
The Food and Drug Administration (FDA) has approved a breakthrough cancer therapy known as CAR-T for use in adults with advanced lymphoma. The therapy uses a patient's own white blood cells, which are modified in a lab and re-trained to recognize specific markers on the surface of the ce...
编者按:2017年9月13日,《新英格兰医学杂志》在线发表(10月5日纸质版)“悲剧、坚持和机遇——CAR-T疗法的故事”(Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy)。《NEJM医学前沿》邀请到美国南卡罗莱纳医科大学李子海教授撰写述评,解读CAR-T历史、进展和挑战。《知识分子》获授权转载。《NEJM医...
CAR-T在实体瘤研究中仅占比20%,但针对实体瘤的 CAR-T 越来越多地涉及难以治疗的癌症,包括胃癌和胰腺癌。 Tecelra的成功无疑会为CAR-T的实体瘤研究提供宝贵的借鉴和思路,相信针对实体瘤的CAR-T疗法批准即将到来。 Ref. Fidler, B. First-of-its-ki...
In 2017, the FDA approved a cutting-edge treatment for diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma. It’s called chimeric antigen receptor T-cell therapy, or CAR T-cell therapy for short. It has been approved for people who have not been helped by other trea...
p>The FDA approved 46 new drugs last year, the highest total in more than two decades.doi:10.1038/nrd.2017.249MullardAsherNat Rev Drug DiscovNature Reviews Drug DiscoveryMullard A. Second anticancer CAR T therapy receives FDA approval. Nat Rev Drug Discov [Internet]. 2017;16(12):818-818. ...
参考文献 https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Receives-Approval-for-Abecma-idecabtagene-vicleucel-the-First-CAR-T-Therapy-Approved-for-the-Treatment-of-Multiple-Myeloma-in-Japan/default.aspx
UPDATED AUGUST 31 //The first T-cell therapy that uses chimeric antigen receptor (CAR) technology has been approved today by the US Food and Drug Administration (FDA), paving the way for the other products using this novel approach that are in development. ...
The FDA gave the green light to Novartis's tisagenlecleucel for the treatment of acute lymphoblastic leukaemia (ALL), marking a historic approval for a first-in-modality chimeric antigen receptor (CAR) T cell therapy. CAR Ts are an ex vivo form of gene therapy, in which T cells are rem...
正是看中了CAR-T极具前景的治疗潜力,今年8月底,吉利德豪掷120亿美元将Kite收购,进军CAR-T领域。(相关阅读:吉利德发力:119亿美金并购CAR-T巨头Kite制药) 原文出处:Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With...